GLIOMATCH selected for Horizon Europe funding

The GLIOMATCH project aimed at advancing precision medicine for brain cancer patients has received a total funding of €12.59 million from the EU, Switzerland, and the UK.

The GLIOMATCH project aimed at advancing precision medicine for brain cancer patients has received a total funding of €12.59 million from the EU, Switzerland, and the UK.